Biomarker Stories

Biomarker testing, which you may have heard referred to as “molecular testing” or “genomic testing,” is done by obtaining a small amount of tissue (called a biopsy) from a patient's tumor, or by drawing a blood sample.

The tissue or blood sample is tested at a lab, which can provide information about a patient's tumor. Results from biomarker testing help to develop a personalized treatment path, including whether targeted therapy is appropriate for the patient.

The Foundation teamed up with Bayer Pharmaceuticals to share eight patient stories for whom biomarker testing positively impacted. A list of known biomarkers and how prevalent they are in cancers is provided for your review. Additional information and resources are also provided.

Bayer Logo

Some Common Biomarkers

TMB

Tumor mutational burden (TMB) is measured by counting the number of reported somatic alterations. It can be measured in molecular profiling tests using tissue samples or liquid biopsy. According to the number of alterations, tumors are classified into low, intermediate, and high-TMB. Several studies showed that TMB is a predictor of treatment response, and patients with TMB-high have a better response to immunotherapy.

MSI
NTRK
ATM D2320N
ALK
EGFR
ERRFl1
BRAF
ROS1
NOTCH1
IDH2 R172K
PIK3CA E542K
MDM2